Specialty pharmaceutical company Encube Ethicals has filed preliminary papers with capital markets regulator Sebi for an Initial Public Offering (IPO) worth Rs 3,000 crore.
The Mumbai-based company's maiden public offering is completely an offer for sale by the promoter Mehul Madhusudan Shah and existing shareholder Frontier Investment Holdings Pte. Ltd, according to the Draft Red Herring Prospectus (DRHP) filed on Friday.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
Since it's an OFS, the company will not receive any proceeds from the public issue, instead funds will go to selling shareholders.
Founded in 1995, the company is a global specialty pharmaceutical formulations platform with deep domain expertise in technically complex topical and transdermal dosage forms, serving 50 countries, including regulated markets such as the United States, UK and Europe, and India as of March 31, 2026.
ALSO READ: Job Maket Watch: Insurance Climbs, Banking Sinks — Check Scorecard Of Top 15 Sectors
The company's manufacturing facilities have accreditations from 11 regulatory authorities, including the US Food and Drug Administration (USFDA), EU GMP, Japan PMDA, Health Canada, Brazil ANVISA and TGA Australia. Its operations are supported by a workforce of 1,684 employees as of March 31, 2026
The company offers end-to-end development and manufacturing services to over 160 pharmaceutical firms across 50 countries.
On the financial front, its revenue from operations was at Rs 1,848.7 crore and its net profit at Rs 436.7 crore during FY26.
JM Financial, Axis Capital, and Kotak Mahindra Capital Company are the book running lead managers, and MUFG Intime India is the registrar to the issue. The shares are proposed to be listed on the BSE and NSE.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.